Antibiotic Selection and Effectiveness for Common Bacterial Infections

Overview of Antibiotic Selection

The Infectious Diseases Society of America recommends that the selection of antibiotics must be guided by infection site, severity, and local resistance patterns, with beta-lactam/beta-lactamase inhibitor combinations and third-generation cephalosporins plus metronidazole serving as the backbone of empiric therapy for most community-acquired infections 1, 2

For mild acute bacterial rhinosinusitis without recent antibiotic use, the American Academy of Otolaryngology-Head and Neck Surgery recommends first-line treatment with amoxicillin-clavulanate, which provides 91-92% clinical efficacy and 97-99% bacteriologic efficacy 4
For non-severe community-acquired pneumonia, the Infectious Diseases Society of America recommends treatment with penicillin G, aminopenicillin plus macrolides, co-amoxiclav plus macrolides, or 2nd/3rd generation cephalosporin plus macrolides 3

For community-acquired, mild-to-moderate severity intra-abdominal infections, the Infectious Diseases Society of America recommends first-line options including ampicillin-sulbactam, cefazolin or cefuroxime plus metronidazole, ticarcillin-clavulanate, ertapenem, or ciprofloxacin or levofloxacin plus metronidazole 1
For severe infections or immunosuppressed patients, the Infectious Diseases Society of America recommends treatment with piperacillin-tazobactam, meropenem or imipenem-cilastatin, or cefotaxime, ceftriaxone, ceftizoxime, ceftazidime, or cefepime plus metronidazole 1, 3

For impetigo, the American Academy of Pediatrics recommends treatment with oral dicloxacillin, cefalexin, erythromycin, clindamycin, or amoxicillin-clavulanate 3
For MRSA infections, the Infectious Diseases Society of America recommends first-line treatment with vancomycin, linezolid, clindamycin, daptomycin, ceftaroline, doxycycline, or sulfamethoxazole-trimethoprim 3

Ceftriaxone plus metronidazole provides coverage against gram-positive cocci, gram-negative aerobic/facultative bacilli, and anaerobic bacteria, but has critical gaps in coverage against Pseudomonas aeruginosa, Enterococcus species, and atypical organisms 2

The Infectious Diseases Society of America recommends a standard duration of 5-7 days of appropriate therapy for most community-acquired infections, and 10-14 days for severe infections 3

The Infectious Diseases Society of America recommends avoiding the use of fluoroquinolones as first-line therapy due to increasing resistance concerns 3
The Infectious Diseases Society of America recommends avoiding the use of clindamycin for B. fragilis infections without checking local susceptibility patterns 1, 3